Genetic Technologies Processes First BREVAGen Patient Sample

Genetic Technologies Limited GENE has received and processed its first BREVAGen™ clinical sample from a US patient. This follows last month's receipt of certification of its Australian laboratory under the US Clinical Laboratories Improvements Amendments. The sample was received by Phenogen Sciences, the Company's new North American subsidiary, where the cheek swab sample was bar-coded and entered into the Laboratory Information Management System, before being priority shipped to Australia for processing. Subsequently the results were made electronically accessible to the Company's North Carolina offices for immediate distribution to the requesting physician. All systems functioned as expected and no infrastructure hurdles remain to full market availability.